Stuart L. Goldberg, M.D

Hematologist/oncologist Stuart L. Goldberg, M.D., specializes in treating all types of leukemia and myelodysplastic syndromes with a variety of treatment modalities, including chemotherapy and stem cell transplantation. Dr. Goldberg led a team of researchers in the Division of Leukemia that participated in international clinical trials that were integral to the U.S. Food and Drug Administration's approval of Gleevec and Sprycel, two revolutionary new targeted therapies to treat chronic myeloid leukemia (CML). Gleevec, approved in 2001, and Sprycel, approved in 2006, work by turning off the abnormal protein in cancer cells produced by the Philadelphia chromosome that causes CML. Both drugs, which are taken in pill form every day, target cancer cells and spare normal healthy ones. He is the author of more than 100 research publications. Click here for a list of John Theurer Cancer Center Leukemia clinical trials.
 

  • Associate Clinical Professor of Medicine, University of Medicine and Dentistry of New Jersey-New Jersey Medical School
  • Medical Education: Pennsylvania State University/Milton S. Hershey Medical Center
  • Residency: Internal medicine, George Washington University Medical Center
  • Fellowships: Hematology/oncology, George Washington University Medical Center; bone marrow transplantation visiting fellow, Fred Hutchinson Cancer Research Center, Seattle; and bone marrow transplantation fellowship, Mayo Clinic and Foundation, Rochester, MN
  • Board Certifications/Eligible: Medical oncology, hematology, internal medicine
  • Specializations: leukemia, myelodysplastic syndromes, bone marrow failure syndromes, hematology, medical oncology, stem cell transplantation. Patients with leukemia come to The Cancer Center from all over the U.S. because of the clinical trials run by Dr. Goldberg and the access they get to new and innovative treatments.
  • Research Interests: Major research in novel targeted therapies for chronic myeloid leukemia; others include novel targeted therapies for leukemia, stem cell transplantation. Dr. Goldberg is among a select few doctors in the country to whom pharmaceutical companies turn to launch new clinical trials for leukemia.
  • Honors/Awards: Fifth District AHEPA Cancer Research Foundation Grant Award, American College of Physicians representative to the Centers for Disease Control and INTOs conference on guidelines for the prevention of opportunistic infections in bone marrow transplant patients
  • Memberships: American College of Physicians, American Society of Blood and Marrow Transplantation, American Society of Hematology, American Society of Clinical Oncology.